Bouygues wins deal to build Valneva’s Scottish COVID-19 vaccine manufacturing facility
Bouygues Energies & Services, a subsidiary of Bouygues Construction, has been selected by Valneva, a speciality vaccine company, for the turnkey design and build of its manufacturing facility in Livingston.
The manufacturing facility is formed of:
- A new Multi Vaccine Facility (MVF), adjacent to the existing vaccine facility, which will be designed to EU GMP Grade A to D cleanroom standards. The facility will house two manufacturing streams and QC testing laboratories uninterruptedly working to produce Valneva’s inactivated whole-virus COVID-19 vaccine. All areas where the live virus will be handled will be designed to meet the requirements of ACDP containment level 3 as agreed with the Health and Safety Executive.
- A new warehouse facility that will consist of temperature-controlled storage areas along with goods in and off-loading bays.
- An energy centre that will shelter all essential plant services to serve the main manufacturing facility and associated labs.
- Shared hub facilities that will comprise the main site entrance, offices, employee’s welfare areas as well as the staff car park and the access road for the delivery.
As the main design and build partner Bouygues Energies & Services will be responsible for the industrial park development, as a turnkey design and build solution.
This project started with a site master planning and detailed design now progressing to engineering, build, commissioning and validation of the new facilities which will be delivered on a phased basis.
The master planning of the industrial park has started in July 2020, and the production of vaccines will commence in the first half of 2021.
Bouygues Energies & Services Contracting managing director Steven Weir said: “We have an excellent track record working with Valneva and are extremely proud to continue with them on this landmark project. We hope that in doing so we can play our small part in the production of this very important vaccine.”
Bouygues Energies & Services said it is committed to supporting Valneva to scale up its manufacturing capacity to be able to produce required doses of the COVID-19 vaccine. The facility will also ensure the readiness for future vaccine development and manufacturing.
David Lawrence, acting CFO of Valneva, added: “Valneva is proud to be contributing to the global need for solutions to address the COVID-19 disease. Our partnership with the UK Government will ensure that our Livingston facility is well prepared to deliver a COVID-19 vaccine during 2021 and beyond.
“Bouygues Energies & Services is a tried and tested partner, we’re working closely with them to ensure that the project is delivered as quickly as possible.”